• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌检测示范项目参与者后续发生的乳腺及其他恶性肿瘤。

Subsequent mammary and other malignant neoplasms in participants of the Breast Cancer Detection Demonstration Project.

作者信息

Lee Y T

出版信息

Prog Clin Biol Res. 1984;156:97-106.

PMID:6473455
Abstract

Among 3,528 BCDP-USC screenees, women who had breast cancer before entering the screening program (Group IA) or who had breast cancer detected during the program (Group IB) had a much higher chance of developing a breast cancer later (second primary) than those without any breast cancers (Group II, III, IV). With a median follow-up of seven years after the initial visit (1974-1976), the chances of developing a breast cancer during follow-up study are 24%, 7%, and 0.8% respectively. On the other hand, the chances of developing non-mammary malignancy are not too different between the various cohort groups (2.0-3.3%). Computer analysis of a selected Triad subgroups (487 screenees) also showed that the overall age-specific cancer incidences of our population are similar to that of the 1973-1977 SEER's data. When the relative frequency of specific site of 137 malignancies is concerned, we did see a few more cases of leukemia and melanoma than the SEER's data. However, the number of cases involved is small. Follow-up of all screenees will be continued, and this is only a preliminary report.

摘要

在3528名参加乳腺癌检测项目-南加州大学筛查的对象中,在进入筛查项目之前就患有乳腺癌的女性(IA组)或在项目期间检测出患有乳腺癌的女性(IB组),比那些没有患过任何乳腺癌的女性(II组、III组、IV组)日后发生乳腺癌(第二原发性乳腺癌)的几率要高得多。在首次就诊(1974 - 1976年)后进行了为期七年的中位随访,随访研究期间发生乳腺癌的几率分别为24%、7%和0.8%。另一方面,不同队列组发生非乳腺恶性肿瘤的几率差异不大(2.0 - 3.3%)。对选定的三联亚组(487名筛查对象)进行的计算机分析还表明,我们人群中按年龄划分的总体癌症发病率与1973 - 1977年美国癌症监测、流行病学和最终结果计划(SEER)的数据相似。当涉及137种恶性肿瘤的特定部位的相对频率时,我们确实发现白血病和黑色素瘤的病例比SEER的数据略多。然而,所涉及的病例数量很少。所有筛查对象的随访将继续进行,这只是一份初步报告。

相似文献

1
Subsequent mammary and other malignant neoplasms in participants of the Breast Cancer Detection Demonstration Project.乳腺癌检测示范项目参与者后续发生的乳腺及其他恶性肿瘤。
Prog Clin Biol Res. 1984;156:97-106.
2
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.预防性卵巢切除术:降低美国上皮性卵巢癌死亡率。一场持续的争论。
Oncologist. 1996;1(5):326-330.
3
Progress report on American Cancer Society/National Cancer Institute Breast Cancer Detection Demonstration Projects.
Prog Clin Biol Res. 1977;12:177-88.
4
Mammography screening for breast cancer in Copenhagen April 1991-March 1997. Mammography Screening Evaluation Group.1991年4月至1997年3月哥本哈根乳腺癌的乳腺X线筛查。乳腺X线筛查评估小组。
APMIS Suppl. 1998;83:1-44.
5
Age-specific interval breast cancers in New South Wales and meta-analysis of studies of women aged 40-49 years.新南威尔士州特定年龄间隔期乳腺癌及40 - 49岁女性研究的荟萃分析。
J Med Screen. 2004;11(4):199-206. doi: 10.1258/0969141042467403.
6
Strategies for improving melanoma education and screening for men age >or= 50 years: findings from the American Academy of Dermatological National Skin Cancer Sreening Program.改善50岁及以上男性黑色素瘤教育与筛查的策略:美国皮肤科学院全国皮肤癌筛查项目的研究结果
Cancer. 2002 Oct 1;95(7):1554-61. doi: 10.1002/cncr.10855.
7
Improved screening for breast cancer associated with a telephone-based risk assessment.
Prev Med. 1998 May-Jun;27(3):493-501. doi: 10.1006/pmed.1998.0313.
8
Service screening with mammography in Northern Sweden: effects on breast cancer mortality - an update.瑞典北部乳腺钼靶筛查服务:对乳腺癌死亡率的影响——最新情况
J Med Screen. 2007;14(2):87-93. doi: 10.1258/096914107781261918.
9
Health maintenance and screening in breast cancer survivors in the United States.美国乳腺癌幸存者的健康维护与筛查
Cancer Detect Prev. 2006;30(1):52-7. doi: 10.1016/j.cdp.2005.06.012. Epub 2006 Feb 7.
10
[Population screening for breast cancer: an interim assessment].[乳腺癌人群筛查:中期评估]
Ned Tijdschr Geneeskd. 2000 Jun 3;144(23):1096-9.